Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hospira, Inc. (HSP): Hedge Funds Are Bearish and Insiders Are Undecided, What Should You Do?

Page 1 of 2

To the average investor, there are a multitude of gauges shareholders can use to analyze their holdings. Two of the most useful are hedge fund and insider trading sentiment. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the elite investment managers can outperform the S&P 500 by a superb amount (see just how much).

Equally as crucial, bullish insider trading activity is a second way to look at the financial markets. There are many stimuli for an executive to drop shares of his or her company, but just one, very simple reason why they would buy. Various academic studies have demonstrated the valuable potential of this tactic if shareholders understand what to do (learn more here).

Hospira, Inc. (NYSE:HSP)

What’s more, let’s examine the newest info for Hospira, Inc. (NYSE:HSP).

What does the smart money think about Hospira, Inc. (NYSE:HSP)?

At the end of the second quarter, a total of 18 of the hedge funds we track were long in this stock, a change of -14% from the previous quarter. With hedge funds’ capital changing hands, there exists an “upper tier” of key hedge fund managers who were boosting their stakes substantially.

According to our 13F database, Harris Associates, managed by Natixis Global Asset Management, holds the most valuable position in Hospira, Inc. (NYSE:HSP). Harris Associates has a $248.7 million position in the stock, comprising 0.5% of its 13F portfolio. Coming in second is John W. Rogers of Ariel Investments, with a $184.3 million position; the fund has 3% of its 13F portfolio invested in the stock. Remaining hedgies with similar optimism include Larry Robbins’s Glenview Capital, Thomas Ellis and Todd Hammer’s North Run Capital and Richard S. Pzena’s Pzena Investment Management.

As Hospira, Inc. (NYSE:HSP) has experienced a fall in interest from upper-tier hedge fund managers, it’s safe to say that there was a specific group of money managers that decided to sell off their entire stakes in Q1. It’s worth mentioning that Dmitry Balyasny’s Balyasny Asset Management cut the biggest stake of the 450+ funds we track, valued at close to $38.3 million in stock. Frank Brosens’s fund, Taconic Capital, also dropped its stock, about $23 million worth. These transactions are intriguing to say the least, as total hedge fund interest fell by 3 funds in Q1.

How are insiders trading Hospira, Inc. (NYSE:HSP)?

Insider buying made by high-level executives is best served when the company in focus has experienced transactions within the past six months. Over the latest six-month time period, Hospira, Inc. (NYSE:HSP) has experienced zero unique insiders buying, and zero insider sales (see the details of insider trades here).

We’ll go over the relationship between both of these indicators in other stocks similar to Hospira, Inc. (NYSE:HSP). These stocks are Delcath Systems, Inc. (NASDAQ:DCTH), Petmed Express Inc (NASDAQ:PETS), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Alkermes Plc (NASDAQ:ALKS), and Elan Corporation, plc (ADR) (NYSE:ELN). This group of stocks are in the drug delivery industry and their market caps match HSP’s market cap.

Page 1 of 2
Loading Comments...